CN114470080A - 一种健脑安神的组合物及其制备方法 - Google Patents
一种健脑安神的组合物及其制备方法 Download PDFInfo
- Publication number
- CN114470080A CN114470080A CN202210169726.2A CN202210169726A CN114470080A CN 114470080 A CN114470080 A CN 114470080A CN 202210169726 A CN202210169726 A CN 202210169726A CN 114470080 A CN114470080 A CN 114470080A
- Authority
- CN
- China
- Prior art keywords
- parts
- composition
- brain
- strengthening
- poria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 61
- 238000005728 strengthening Methods 0.000 title claims abstract description 34
- 238000002360 preparation method Methods 0.000 title abstract description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 52
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims abstract description 32
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 19
- 244000197580 Poria cocos Species 0.000 claims abstract description 19
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 19
- 210000004556 brain Anatomy 0.000 claims abstract description 19
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 210000005036 nerve Anatomy 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims description 40
- 239000000284 extract Substances 0.000 claims description 33
- 230000002936 tranquilizing effect Effects 0.000 claims description 21
- 241000208340 Araliaceae Species 0.000 claims description 16
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 16
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 16
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 16
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 15
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 15
- 235000008434 ginseng Nutrition 0.000 claims description 15
- 229930006000 Sucrose Natural products 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 14
- 239000008188 pellet Substances 0.000 claims description 14
- 210000000582 semen Anatomy 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 238000010298 pulverizing process Methods 0.000 claims description 12
- 238000007873 sieving Methods 0.000 claims description 12
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 10
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 10
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 10
- 244000274050 Platycodon grandiflorum Species 0.000 claims description 9
- 241001080798 Polygala tenuifolia Species 0.000 claims description 9
- 235000006753 Platycodon grandiflorum Nutrition 0.000 claims description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000011230 binding agent Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 239000011812 mixed powder Substances 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 3
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 claims description 2
- 239000004925 Acrylic resin Substances 0.000 claims description 2
- 229920000178 Acrylic resin Polymers 0.000 claims description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 2
- 239000001856 Ethyl cellulose Substances 0.000 claims description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 150000001720 carbohydrates Chemical class 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 2
- 229920001249 ethyl cellulose Polymers 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000003292 glue Substances 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000010981 methylcellulose Nutrition 0.000 claims description 2
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 241000208689 Eucommia ulmoides Species 0.000 claims 2
- 230000000694 effects Effects 0.000 abstract description 35
- 238000000605 extraction Methods 0.000 abstract description 6
- 230000036039 immunity Effects 0.000 abstract description 5
- 239000002904 solvent Substances 0.000 abstract description 2
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 15
- 208000026435 phlegm Diseases 0.000 description 15
- 239000003814 drug Substances 0.000 description 11
- 238000001914 filtration Methods 0.000 description 10
- 238000005303 weighing Methods 0.000 description 10
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 9
- 206010022437 insomnia Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 230000010355 oscillation Effects 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000008901 benefit Effects 0.000 description 6
- 244000237330 gutta percha tree Species 0.000 description 6
- 206010033557 Palpitations Diseases 0.000 description 5
- 230000001914 calming effect Effects 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 208000000044 Amnesia Diseases 0.000 description 4
- 208000031091 Amnestic disease Diseases 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 230000006986 amnesia Effects 0.000 description 4
- 206010003549 asthenia Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 240000007185 Albizia julibrissin Species 0.000 description 3
- 235000011468 Albizia julibrissin Nutrition 0.000 description 3
- 206010007247 Carbuncle Diseases 0.000 description 3
- 206010008479 Chest Pain Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 235000003805 Musa ABB Group Nutrition 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 208000007443 Neurasthenia Diseases 0.000 description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 235000001188 Peltandra virginica Nutrition 0.000 description 3
- 201000007100 Pharyngitis Diseases 0.000 description 3
- 235000015266 Plantago major Nutrition 0.000 description 3
- 208000033809 Suppuration Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 230000036528 appetite Effects 0.000 description 3
- 235000019789 appetite Nutrition 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010010071 Coma Diseases 0.000 description 2
- 206010011878 Deafness Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 206010013954 Dysphoria Diseases 0.000 description 2
- 241000208688 Eucommia Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 241001127637 Plantago Species 0.000 description 2
- 241000208966 Polygala Species 0.000 description 2
- 241000222341 Polyporaceae Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 231100000895 deafness Toxicity 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 208000016354 hearing loss disease Diseases 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 229930182490 saponin Natural products 0.000 description 2
- 150000007949 saponins Chemical class 0.000 description 2
- 235000017709 saponins Nutrition 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 206010000242 Abortion threatened Diseases 0.000 description 1
- 206010063409 Acarodermatitis Diseases 0.000 description 1
- 244000205574 Acorus calamus Species 0.000 description 1
- 235000006480 Acorus calamus Nutrition 0.000 description 1
- 244000001632 Acorus gramineus Species 0.000 description 1
- 235000013073 Acorus gramineus Nutrition 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 241000209524 Araceae Species 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010006298 Breast pain Diseases 0.000 description 1
- 206010006312 Breast swelling Diseases 0.000 description 1
- 241000208671 Campanulaceae Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010016807 Fluid retention Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- 239000009636 Huang Qi Substances 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- 206010024642 Listless Diseases 0.000 description 1
- 208000006662 Mastodynia Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 241000234295 Musa Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010030302 Oliguria Diseases 0.000 description 1
- 206010033425 Pain in extremity Diseases 0.000 description 1
- 235000002791 Panax Nutrition 0.000 description 1
- 241000208343 Panax Species 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241001499733 Plantago asiatica Species 0.000 description 1
- 241000961970 Plantago depressa Species 0.000 description 1
- 235000006751 Platycodon Nutrition 0.000 description 1
- 241000208977 Polygalaceae Species 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 208000008350 Pruritus Vulvae Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 241000447727 Scabies Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 208000005985 Threatened Abortion Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010056530 Vulvovaginal pruritus Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- RKFAZBXYICVSKP-AATRIKPKSA-N alpha-asarone Chemical group COC1=CC(OC)=C(\C=C\C)C=C1OC RKFAZBXYICVSKP-AATRIKPKSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000001088 anti-asthma Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 239000000924 antiasthmatic agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 210000003756 cervix mucus Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 206010016766 flatulence Diseases 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 208000006750 hematuria Diseases 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000017971 listlessness Diseases 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 201000003453 lung abscess Diseases 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000004630 mental health Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 description 1
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229930189914 platycodon Natural products 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 208000005687 scabies Diseases 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000009396 suanzaoren Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 235000019605 sweet taste sensations Nutrition 0.000 description 1
- 206010042772 syncope Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- 230000008736 traumatic injury Effects 0.000 description 1
- 229930182493 triterpene saponin Natural products 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 229940126673 western medicines Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/346—Platycodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/46—Eucommiaceae (Eucommia family), e.g. hardy rubber tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/68—Plantaginaceae (Plantain Family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/69—Polygalaceae (Milkwort family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明涉及中药技术领域,具体而言,涉及一种健脑安神的组合物及其制备方法。一种健脑安神的组合物,按重量份数计包括以下原料:茯神40‑60份、茯苓40‑60份、红参40‑60份和石菖蒲40‑60份。该组合物成分简单,配伍合理,能增强记忆力、提高人体免疫力、醒神益智、宁心安神、促进睡眠等,有助于健脑安神以且副作用小。本发明还提供一种健脑安神的组合物的制备方法,采用乙醇作为提取溶剂,在超声仪中进行提取,操作简单。
Description
技术领域
本发明涉及中药技术领域,具体而言,涉及一种健脑安神的组合物及其制备方法。
背景技术
现代社会,人们的生活节奏越来越快,生活压力也越来越大。长期处于快节奏的人容易出现神经衰弱,例如烦躁不安,精神倦怠,失眠多梦等神经衰弱症状,长此以往,甚至会引发心悸,胸闷、筋骨酸痛,四肢乏力,腰酸腿痛等其他症状,甚至可能引发高血压,冠心病,癌症等疾病,严重影响人们的身心健康。此外,大多数人都处于亚健康状态,记忆力减退,免疫力下降。
目前,用于治疗缓解上述病症的药物大多为西药,西药治标不治本,长期服用副作用大。一般的生物制剂治疗效果易反复,药物依赖性大,对肝脏损害大,长期使用导致机体损害、免疫力下降,导致并发症的产生,无法更好的为患者减轻痛苦。
发明内容
本发明的目的在于提供一种健脑安神的组合物,该组合物能增强记忆力、提高人体免疫力、醒神益智、宁心安神、促进睡眠等,有助于健脑安神且副作用小。
本发明的另一目的在于提供一种健脑安神的组合物的制备方法,其制备方法简单、便于操作。
本发明解决其技术问题是采用以下技术方案来实现的。
一方面,本发明实施例提供一种健脑安神的组合物,按重量份数计包括以下原料:茯神40-60份、茯苓40-60份、红参40-60份和石菖蒲40-60份。
另一方面,本发明实施例提供一种健脑安神的组合物的制备方法,其包括:称取茯神、茯苓、红参、石菖蒲分别粉碎、过筛,再将所得药粉混合,得到混合药粉;加入乙醇,在25-30℃条件下振荡10-12h,振荡后将其放入超声仪中,工作30min-1h后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在制得的提取物中加入赋形剂和粘合剂,制成微丸。
相对于现有技术,本发明的实施例至少具有如下优点或有益效果:
本发明提出一种健脑安神的组合物,以茯神、茯苓、红参、石菖蒲配伍,组分简单,功效甚佳,能增强记忆力、提高人体免疫力、醒神益智、宁心安神、促进睡眠等,有助于健脑安神,且副作用小。
另外,本发明还提出一种健脑安神的组合物的制备方法,其操作简单,提取效率高。
具体实施方式
为使本发明实施例的目的、技术方案和优点更加清楚,下面将对本发明实施例中的技术方案进行清楚、完整地描述。实施例中未注明具体条件者,按照常规条件或制造商建议的条件进行。所用试剂或仪器未注明生产厂商者,均为可以通过市售购买获得的常规产品。
需要说明的是,在不冲突的情况下,本发明中的实施例及实施例中的特征可以相互组合。下面将参考具体实施例来详细说明本发明。
一方面,本发明实施例提供一种健脑安神的组合物,按重量份数计包括以下原料:茯神40-60份、茯苓40-60份、红参40-60份和石菖蒲40-60份。
茯神,为多孔菌科植物茯苓菌核中间天然抱有松根(即茯神木)的白色部分。其味甘淡,性平。具有宁心,安神,利尿的功效。用于治疗心虚惊悸,健忘,失眠,惊痫,小便不利。茯神具有镇静作用,可以沉香配伍,治疗心神不定,可与人参、黄耆、熟干地黄、当归、酸枣仁、朱砂等配伍治疗精神恍惚、睡卧不宁。其化学成分主要为多糖类,茯苓酸,蛋白质,脂肪,卵磷脂,胆碱,组氨酸等,有抗胃溃疡,保护肝细胞,增强心肌收缩力,增快心率、中枢抑制作用,降低过度兴奋、利尿作用。此外还有降血糖,抗肿瘤,抗病原微生物,促进造血功能等。
茯苓,为多孔菌科真菌茯苓的干燥菌核。其味甘、淡,性平。具有利水渗湿,健脾,宁心的功效。用于治疗水肿尿少,痰饮眩悸,脾虚食少,便溏泄泻,心神不安,惊悸失眠。茯苓的化学成分主要是多糖类、三萜类、甾醇类等,多糖作为茯苓中的主要成分之一,具有抗肿瘤、抗炎、保肝、调节免疫功能等药理活性,还能在一定程度上抗抑郁、抑菌和降血糖。
红参,五加科人参属植物,性温,味甘、微苦。具有大补元气,复脉固脱,益气摄血的功效。多用于治疗体虚欲脱,肢冷脉微,气不摄血,崩漏下血。红参的主要成分是三萜皂苷,还含有挥发油、多糖、氨基酸、微量元素、多肽等。其中,红参的三萜皂苷、多糖是其主要药理活性成分,能调节神经、心血管及内分泌***,促进机体物质代谢及蛋白质和RNA、DNA的合成。红参对中枢神经***具有兴奋作用,而量较大时反而有抑制作用,能加强动物高级神经活动的兴奋和抑制过程,此外,红参还能增强机体对一切非特异性刺激的适应能力,能减少疲劳感。
石菖蒲,天南星科菖蒲属植物,性微温,味辛、苦。其具有化湿开胃,开窍豁痰,醒神益智的功效。用于治疗脘痞不饥,噤口下痢,神昏癫痫,健忘耳聋;理气,活血,散风,去湿;治癫痫,痰厥,热病神昏,健忘,气闭耳聋,心胸烦闷,胃痛,腹痛,风寒湿痹,痈疽肿毒,跌打损伤。石菖蒲与生姜配伍可治疗痰迷心窍。石菖蒲根茎含挥发油,其主要成分是细辛醚,细辛醚是镇静的有效成分,具有镇静、抗惊厥、改善记忆再现缺失、镇咳祛痰、解痉、抗菌、抗心律失常、降血脂、开窍、抗肿瘤等药理作用。此外,石菖蒲还具有抗真菌、平喘镇咳、改善消化机能等作用。
在本发明的一些实施例中,按重量份数计还可以包括以下原料:车前子10-20份、桔梗8-10份和薄荷8-10份。
车前子,为车前科植物车前或平车前的干燥成熟种子,味甘,性寒。具有利水,清热,明目,祛痰的功效。用于治疗小便不通,淋浊,带下,尿血,暑湿泻痢,咳嗽多痰,湿痹,目赤障翳。
桔梗,桔梗科桔梗属植物,宣肺,利咽,祛痰,排脓。用于咳嗽痰多,胸闷不畅,咽痛,音哑,肺痈吐脓,疮疡脓成不溃。桔梗根中含多种皂甙,其中的桔梗皂苷有明显的祛痰、抗炎、降血糖作用,还可镇静、镇痛和解热。
薄荷,味辛,性凉。具有疏散风热,清利头目,利咽透疹,疏肝行气的功效。用于治疗外感风热,头痛,咽喉肿痛,食滞气胀,口疮,牙痛,疮疥,瘾疹,温病初起,风疹瘙痒,肝郁气滞,胸闷胁痛。与柴胡、白芍、当归等配伍可用于治疗肝郁气滞。
在本发明的一些实施例中,按重量份数计还可以包括以下原料:远志10-20份、杜仲10-20份和合欢皮10-20份。
远志,远志科远志属植物,多年生草本,主根粗壮,韧皮部肉质。味苦、辛、性温。具有安神益智、祛痰、消肿的功能,用于心肾不交引起的失眠多梦、健忘惊悸,神志恍惚,咳痰不爽,疮疡肿毒,***肿痛。
杜仲,为杜仲科杜仲属植物,以树皮入药,味甘微辛,性温。具有补益肝肾,强筋活络,定气安神之功效。用于治疗腰脊酸疼,足膝痿弱,小便余沥,阴下湿痒,胎漏欲堕,胎动不安,高血压。
合欢皮,为豆科植物合欢的干燥树皮,性味甘、平。有解郁、和血、宁心、消痈肿之功。有治心神不安、忧郁、失眠、肺痈、痈肿、瘰疠、筋骨折伤之效。常用于情志不遂忧郁而致失眠者、心神不宁等下,临床多与柏子仁、丹参、酸枣仁等同用,以增强养心开郁、安神定志作用。
在本发明的一些实施例中,按重量份数计可以包括以下原料:茯神50份、茯苓50份、红参50份、石菖蒲50份、车前子10份、桔梗8份、薄荷8份、远志10份、杜仲10份和合欢皮10份。在该配方中,茯苓、茯神、红参和石菖蒲能镇静、抗炎、宁心安神、增强记忆力,车前子、桔梗和薄荷能疏风散热、利水通淋,祛除体内湿热邪毒,远志、杜仲和合欢皮具有化痰定喘、强劲活络、补益肝肾。该药物配伍精良,组方合理,共奏补益肝肾、疏风散热、润肺化痰、养心安神和促进睡眠之功效,具有较高的安神健脑之功。
另一方面,本发明还提供一种健脑安神的组合物的制备方法,其包括:
S1称取茯神、茯苓、红参、石菖蒲分别粉碎、过筛,再将所得药粉混合,得到混合药粉;
S2加入乙醇,在25-30℃条件下振荡10-12h,振荡后将其放入超声仪中,工作30min-1h后取出得到提取液;
S3对提取液抽滤、浓缩,得到提取物;
S4在S3制得的提取物中加入赋形剂和粘合剂,制成微丸。
该制备方法简单,将组合物制成微丸,便于服用。
在本发明的一些实施例中,所述S2中,所述乙醇的浓度为75-85%。乙醇浓度为75-85%时,抑菌效果较好,可抑制提取过程中一些菌类物质的生长,对药物中有效成分的浸出率也较高。
在本发明的一些实施例中,所述S2中,所述混合药粉与所述溶剂的比例为1:20-1:30。料液比为1:20-1:30时,抑菌效果较好。
在本发明的一些实施例中,所述S2中,超声仪的超声功率为600-800W,工作温度为37-42℃。在温度为37-42℃、超声功率为600-800W的超声仪中提取,能增加提取效率,并且抑菌效果较好。
在本发明的一些实施例中,所述S4中,所述赋形剂为蔗糖、蜂蜜、糊精、淀粉、维晶纤维素、乳糖、甲基纤维素、羧甲基纤维素钠、聚乙烯吡咯烷酮、乙基纤维素、丙烯酸树脂、羟丙基甲基纤维素和明胶中的一种或几种。赋形剂是在药物制剂中除主药以外的附加物,也可称为辅料。这些赋形剂性质稳定,与主药无配伍禁忌,不会产生副作用,不会影响疗效,且在常温下不易变形、干裂、霉变、虫蛀、对人体无害、无生理作用,也不会与主药产生化学或物理作用。
在本发明的一些实施例中,所述S4中,所述粘合剂为聚乙烯吡咯烷酮、纤维素类、树脂类、糖类和动物胶中的一种或几种。粘合剂是最重要的辅助材料之一。其具有粘性,借助其粘性能将各种分离的材料连接在一起。
以下结合实施例对本发明的特征和性能作进一步的详细描述。
实施例1
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神40g、茯苓40g、红参40g和石菖蒲40g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:20,在25℃条件下振荡10h,振荡后将其放入超声仪中,超声功率为600W,温度为37℃,工作30min后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入蔗糖和聚乙烯吡咯烷酮,制成微丸。所述提取物与蔗糖和聚乙烯吡咯烷酮的重量百分比为:50%:20%:30%。
实施例2
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神50g、茯苓50g、红参50g和石菖蒲50g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:25,在26℃条件下振荡12h,振荡后将其放入超声仪中,超声功率为700W,温度为38℃,工作45min后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入蜂蜜,制成微丸。所述提取物与蜂蜜的重量百分比为:37.5%:57.5%。
实施例3
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神60g、茯苓60g、红参60g和石菖蒲60g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:30,在30℃条件下振荡11h,振荡后将其放入超声仪中,超声功率为800W,温度为39℃,工作50min后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入糊精和松香,制成微丸。所述提取物与糊精和松香的重量百分比为:50%:20%:30%。
实施例4
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神40g、茯苓40g、红参40g、石菖蒲40g、车前子10g、桔梗8g和薄荷8g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲、车前子、桔梗和薄荷,分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:24,在30℃条件下振荡10h,振荡后将其放入超声仪中,超声功率为600W,温度为40℃,工作30min后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入蔗糖和聚乙烯吡咯烷酮,制成微丸。所述提取物与蔗糖和聚乙烯吡咯烷酮的重量百分比为:50%:20%:30%。
实施例5
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神50g、茯苓50g、红参50g、石菖蒲50g、车前子15g、桔梗9g和薄荷9g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲、车前子、桔梗和薄荷,分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:20,在30℃条件下振荡12h,振荡后将其放入超声仪中,超声功率为700W,温度为41℃,工作1h后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入蔗糖和聚乙烯吡咯烷酮,制成微丸。所述提取物与蔗糖和聚乙烯吡咯烷酮的重量百分比为:50%:20%:30%。
实施例6
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神50g、茯苓50g、红参50g、石菖蒲50g、车前子20g、桔梗10g和薄荷10g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲、车前子、桔梗和薄荷,分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:25,在30℃条件下振荡12h,振荡后将其放入超声仪中,超声功率为750W,温度为42℃,工作1h后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入蔗糖和聚乙烯吡咯烷酮,制成微丸。所述提取物与蔗糖和聚乙烯吡咯烷酮的重量百分比为:50%:20%:30%。
实施例7
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神40g、茯苓40g、红参40g、石菖蒲40g、车前子10g、桔梗8g、薄荷8g、远志10g、杜仲10g和合欢皮10g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲、车前子、桔梗、薄荷、远志、杜仲和合欢皮,分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:30,在30℃条件下振荡12h,振荡后将其放入超声仪中,超声功率为800W,温度为38℃,工作42min后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入蔗糖和聚乙烯吡咯烷酮,制成微丸。所述提取物与蔗糖和聚乙烯吡咯烷酮的重量百分比为:50%:20%:30%。
实施例8
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神45g、茯苓45g、红参45g、石菖蒲45g、远志20g、杜仲20g和合欢皮20g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲、远志、杜仲和合欢皮,分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:24,在30℃条件下振荡12h,振荡后将其放入超声仪中,超声功率为650W,温度为39℃,工作50min后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入蔗糖和聚乙烯吡咯烷酮,制成微丸。所述提取物与蔗糖和聚乙烯吡咯烷酮的重量百分比为:50%:20%:30%。
实施例9
本实施例的目的在于提供一种健脑安神的组合物,原料如下:
茯神60g、茯苓60g、红参60g、石菖蒲60g、远志15g、杜仲15g和合欢皮15g。
该组合物的具体制备方法如下:
称取茯神、茯苓、红参、石菖蒲、远志、杜仲和合欢皮,分别粉碎、过筛,再将所得药粉混合,得到混合药粉;在混合药粉中加入乙醇,混合药粉与乙醇的比例为1:25,在30℃条件下振荡12h,振荡后将其放入超声仪中,超声功率为600W,温度为42℃,工作50min后取出得到提取液;对提取液抽滤、浓缩,得到提取物;在提取物中加入蜂蜜,制成口服液。所述提取物与蜂蜜的重量百分比为:37.5%:57.5%。
实验例
为进一步考察本发明药物的临床疗效,我们选取90例神经衰弱患者进行临床试验,所有患者均为因工作、生活压力大导致出现了烦躁不安,精神倦怠,失眠多梦、食欲不佳、体弱乏力、记忆力减退等症状,临床诊断为神经衰弱,已经影响到正常的工作和生活。其中男42,女48例,年龄20-48岁,平均30岁。随机分为治疗组1、治疗组2和对照组,每组30例,两组人员的年龄、性别、体重、症状等基线资料经统计学分析,差异无统计学意义(P>0.05),具有可比性。
疗效标准:
治愈:临床症状消失,不影响正常工作及生活;
有效:临床症状改善,食欲增加,失眠、乏力、头晕、头痛等症状好转,记忆力增加;
无效:服药后临床症状无变化或加重。
治疗方法:
治疗组1:取实施例1中的所制得的微丸,一次3.3±0.2g,一日两次,服用30天。
治疗组2:取实施例6中所制得的微丸,一次3.3±0.2g,一日两次,服用30天。
对照组:口服安神健脑片(通化茂祥制药有限公司生产,国药准字Z20026740),一次1片,一日2次。三组均治疗30天后判定疗效。
表1三组患者临床疗效结果对照表
由表1可知,治疗组1治愈11例,有效17例,无效2例,总有效率达93%。治疗组2治愈10例,有效16例,无效4例,总有效率86%。对照组治愈7例,有效13例,无效10例,总有效率66.6%。治疗组效果显著由于对照组,两组比较差异具有统计学意义。并且,在服用过程中,三组患者均没有但明显不良反应,主要安全性指标血、尿、便常规及心电图等治疗前后检测无特殊变化。
结果表明,本发明提供的健脑安神的组合物具有确切疗效,治愈率高,物副作用,且服用方便。
综上所述,本发明实施例提供一种健脑安神的组合物及其制备方法。该组合物以茯苓、茯神、红参和石菖蒲为主要配方,具有镇静、抗炎、宁心安神、增强记忆力,配方简单,副作用小,且对预防老年痴呆也有一定效果。配方中还可以加入车前子、桔梗和薄荷,以疏风散热、利水通淋,祛除体内湿热邪毒。此外,配方中还可加入远志、杜仲和合欢皮,以化痰定喘、强劲活络、补益肝肾。该药物配伍精良,组方合理,补益肝肾、疏风散热、润肺化痰、养心安神和促进睡眠,具有较高的安神健脑之功。
以上所描述的实施例是本发明一部分实施例,而不是全部的实施例。本发明的实施例的详细描述并非旨在限制要求保护的本发明的范围,而是仅仅表示本发明的选定实施例。基于本发明中的实施例,本领域普通技术人员在没有作出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
Claims (10)
1.一种健脑安神的组合物,其特征在于,按重量份数计包括以下原料:茯神40-60份、茯苓40-60份、红参40-60份和石菖蒲40-60份。
2.根据权利要求1所述的健脑安神的组合物,其特征在于,按重量份数计还包括以下原料:车前子10-20份、桔梗8-10份和薄荷8-10份。
3.根据权利要求2所述的健脑安神的组合物,其特征在于,按重量份数计还包括以下原料:远志10-20份、杜仲10-20份和合欢皮10-20份。
4.根据权利要求3所述的健脑安神的组合物,其特征在于,按重量份数计包括以下原料:茯神50份、茯苓50份、红参50份、石菖蒲50份、车前子10份、桔梗8份、薄荷8份、远志10份、杜仲10份和合欢皮10份。
5.一种如权利要求1-4任一项所述的健脑安神的组合物的制备方法,其特征在于,其包括:
S1称取茯神、茯苓、红参、石菖蒲分别粉碎、过筛,再将所得药粉混合,得到混合药粉;
S2加入乙醇,在25-30℃条件下振荡10-12h,振荡后将其放入超声仪中,工作30min-1h后取出得到提取液;
S3对提取液抽滤、浓缩,得到提取物;
S4在S3制得的提取物中加入赋形剂和粘合剂,制成微丸。
6.根据权利要求5所述的健脑安神的组合物的制备方法,其特征在于,所述S2中,所述乙醇的浓度为75-85%。
7.根据权利要求5所述的健脑安神的组合物的制备方法,其特征在于,所述S2中,所述混合药粉与所述乙醇的比例为1:20-1:30。
8.根据权利要求5所述的健脑安神的组合物的制备方法,其特征在于,所述S2中,超声仪的超声功率为600-800W,工作温度为37-42℃。
9.根据权利要求5所述的健脑安神的组合物的制备方法,其特征在于,所述S4中,所述赋形剂为蔗糖、蜂蜜、糊精、淀粉、维晶纤维素、乳糖、甲基纤维素、羧甲基纤维素钠、聚乙烯吡咯烷酮、乙基纤维素、丙烯酸树脂、羟丙基甲基纤维素和明胶中的一种或几种。
10.根据权利要求5所述的健脑安神的组合物的制备方法,其特征在于,所述S4中,所述粘合剂为聚乙烯吡咯烷酮、纤维素类、树脂类、糖类和动物胶中的一种或几种。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210169726.2A CN114470080A (zh) | 2022-02-23 | 2022-02-23 | 一种健脑安神的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210169726.2A CN114470080A (zh) | 2022-02-23 | 2022-02-23 | 一种健脑安神的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114470080A true CN114470080A (zh) | 2022-05-13 |
Family
ID=81484279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210169726.2A Pending CN114470080A (zh) | 2022-02-23 | 2022-02-23 | 一种健脑安神的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114470080A (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062208A (zh) * | 2007-05-23 | 2007-10-31 | 王军 | 远志安心丸 |
CN101181447A (zh) * | 2007-12-11 | 2008-05-21 | 王存银 | 益智不忘散 |
CN104825650A (zh) * | 2015-04-23 | 2015-08-12 | 张辉 | 一种安神健脑口服液 |
CN113577181A (zh) * | 2021-08-18 | 2021-11-02 | 吉林天药本草堂制药有限公司 | 参乌健脑药物组合物 |
-
2022
- 2022-02-23 CN CN202210169726.2A patent/CN114470080A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101062208A (zh) * | 2007-05-23 | 2007-10-31 | 王军 | 远志安心丸 |
CN101181447A (zh) * | 2007-12-11 | 2008-05-21 | 王存银 | 益智不忘散 |
CN104825650A (zh) * | 2015-04-23 | 2015-08-12 | 张辉 | 一种安神健脑口服液 |
CN113577181A (zh) * | 2021-08-18 | 2021-11-02 | 吉林天药本草堂制药有限公司 | 参乌健脑药物组合物 |
Non-Patent Citations (5)
Title |
---|
宋永刚等: "《神农本草经讲读》", 31 January 2018, 中国中医药出版社 * |
张万义等: "《睡眠障碍实用良方》", 31 May 2016, 中国医药科技出版社 * |
张敬礼等: "《寿世补元》", 31 January 2002, 中国医药科技出版社 * |
柴瑞震等: "《便秘吃什么?禁什么?》", 30 June 2014, 黑龙江科学技术出版社 * |
郑育龙等: "《全食物搭配的智慧》", 31 December 2018, 青岛出版社 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106924374B (zh) | 一种组合物及其制备方法与在制备降血糖和/或降血脂的产品中的应用 | |
CN104825914A (zh) | 一种辅助治疗乳腺癌症的中药制剂 | |
CN103301267A (zh) | 一种治疗高血压和/或动脉粥样硬化的中药组合物及应用 | |
CN104206595A (zh) | 一种降脂降糖的地骨皮保健茶及其制备方法 | |
CN114748603B (zh) | 一种防治新冠病毒肺炎变异或复阳的药物组合物和应用 | |
CN101249255B (zh) | 一种治疗小儿咳嗽的中成药及其制备方法 | |
CN107158299B (zh) | 一种具有增强学习记忆力功能的组合物及其制备方法 | |
CN105435197A (zh) | 一种治疗桥本氏病的药物组合物及其制备方法 | |
CN109876127B (zh) | 一种养血当归胶囊及其制备方法 | |
CN112402569A (zh) | 一种抗疲劳保健品及其制备方法 | |
CN108813500B (zh) | 具有补中益气、养血安神和调节人体机能的养生蜂蜜膏 | |
CN114470080A (zh) | 一种健脑安神的组合物及其制备方法 | |
CN111084878A (zh) | 一种用于肺及呼吸***疾病的生物医药、医用全营养食品及制备方法 | |
CN105362630A (zh) | 一种治疗更年期综合症的药物组合物及其制备方法 | |
CN104623615A (zh) | 一种治疗哮喘的药物 | |
CN110882362A (zh) | 一种调理糖尿病的中药食疗制品及其制备方法 | |
CN112823807A (zh) | 一种阿胶人参膏及其制备方法 | |
CN108853340A (zh) | 一种滋养肝肾的中药及其制备方法 | |
CN103520644B (zh) | 用于治疗痰瘀型高脂血症的中药组合物及其制备方法 | |
CN114712466B (zh) | 一种具有减肥养颜功效的药物及其制备方法 | |
CN108324783A (zh) | 白归参灵冬甘治癌药 | |
CN114949114B (zh) | 一种有助于增强免疫力的含沉香中药组合物及其制备方法、制剂与应用 | |
CN100571739C (zh) | 治疗心血管疾病的复方中药及其制备方法 | |
CN105582379A (zh) | 一种治疗肝胃不和的中药组合物及其制备方法 | |
CN105456933A (zh) | 一种活血化瘀、通经活络的中药及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220513 |